Clinical Trials Logo

Myeloma Multiple clinical trials

View clinical trials related to Myeloma Multiple.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03191981 Withdrawn - Myeloma Multiple Clinical Trials

Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma

MUKfourteen
Start date: August 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-centre phase I/II trial with an initial dose finding phase for cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab for patients with relapsed or relapsed / refractory multiple myeloma (MM) that have had at least 1 prior line of therapy

NCT ID: NCT02447055 Withdrawn - Multiple Myeloma Clinical Trials

Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma

Start date: December 2015
Phase: Phase 0
Study type: Interventional

The purpose of this study is to develop a novel platform for allo-SCT in multiple myeloma (MM) with the idea of maximizing anti-myeloma effect with conditioning and minimizing GvHD (graft versus host disease). Specifically, the investigators will use the Flu/Mel (fludarabine and melphalan) regimen. For GvHD prophylaxis, the investigators use the Hopkins PT-Cy (post-transplant cyclophosphamide) platform with the novelty of adding tocilizumab as both an anti-myeloma therapy and as a method to reduce GvHD. IL-6 has an important role in promoting the growth of myeloma cells and progression of disease.